Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis.

Taku KobayashiEri UdagawaAkihito UdaToshifumi HibiTadakazu Hisamatsu

Published in: Journal of gastroenterology and hepatology (2019)

Adding infliximab to an existing IM results in a lower probability of nonpersistence compared with infliximab monotherapy in ulcerative colitis patients. This effect is not seen in adalimumab-treated patients.

Keyphrases

ulcerative colitis
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
emergency department
rheumatoid arthritis
clinical trial
health insurance
study protocol
patient reported
disease activity